Encorafenib Dosage
Medically reviewed by Drugs.com. Last updated on Apr 26, 2023.
Applies to the following strengths: 50 mg; 75 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Melanoma - Metastatic
450 mg orally once a day in combination with binimetinib until disease progression or unacceptable toxicity
NOTE: If binimetinib is withheld, reduce encorafenib to a maximum dose of 300 mg once a day until binimetinib is resumed.
Comments:
- Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating therapy.
- Refer to the binimetinib prescribing information for recommended dosing information.
Use: This drug, in combination with binimetinib, is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test
Usual Adult Dose for Colorectal Cancer
300 mg orally once a day in combination with cetuximab until disease progression or unacceptable toxicity
Comments:
- Confirm the presence of a BRAF V600E mutation in tumor specimens prior to initiating therapy.
- Refer to the cetuximab prescribing information for recommended dosing information.
Use: This drug, in combination with cetuximab, is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy
Renal Dose Adjustments
Mild to moderate renal impairment (CrCl 30 to less than 90 mL/min): No adjustment recommended.
Severe renal impairment (CrCl less than 30 mL/min): Dose adjustment may be required; however, no specific guidelines have been suggested.
Liver Dose Adjustments
Mild hepatic (Child-Pugh A) impairment: No adjustment recommended.
Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment: Dose adjustment may be required; however, no specific guidelines have been suggested.
Dose Adjustments
BRAF V600E OR V600K MUTATION-POSITIVE UNRESECTABLE OR METASTATIC MELANOMA:
- If binimetinib is withheld, reduce encorafenib to a maximum dose of 300 orally mg once a day until binimetinib is resumed.
- If cetuximab is discontinued, discontinue binimetinib.
- First dose reduction: 300 mg orally once a day
- Second dose reduction: 225 mg orally once a day
- Subsequent modification: Permanently discontinue this drug if unable tolerate 225 mg once a day.
BRAF V600E MUTATION-POSITIVE METASTATIC COLORECTAL CANCER (CRC):
- If cetuximab is discontinued, discontinue binimetinib.
- First dose reduction: 225 mg orally once a day
- Second dose reduction: 150 mg orally once a day
- Subsequent modification: Permanently discontinue this drug if unable tolerate 150 mg once a day.
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma and BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC):
NEW PRIMARY MALIGNANCIES:
- Non-cutaneous RAS mutation-positive malignancies: Discontinue this drug.
- Grade 1 through 3: If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold this drug for up to 6 weeks; if improved, resume at same or reduced dose; if not improved, permanently discontinue this drug.
- Grade 4: Permanently discontinue therapy.
- QTcF greater than 500 milliseconds (ms) and less than or equal to 60 ms increase from baseline: Withhold this drug until QTcF is less than or equal to 500 ms; resume at reduced dose; if more than one recurrence, permanently discontinue this drug.
- QTcF greater than 500 ms and greater than 60 ms increase from baseline: Permanently discontinue this drug.
- Grade 2 AST or ALT increased: Maintain the dose; if no improvement within 4 weeks, withhold this drug until improvement to Grade 0 or 1 or to pretreatment/baseline levels and then resume at same dose.
- Recurrent Grade 2 or first occurrence of any Grade 3 AST or ALT increased: Withhold this drug for up to 4 weeks; if improvement to Grade 0 or 1 or to pretreatment/baseline level, resume at reduced dose; if no improvement, permanently discontinue this drug.
- First occurrence of any Grade 4 AST or ALT increase: Permanently discontinue this drug OR withhold this drug for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug.
- Recurrent Grade 3 AST or ALT increased: Consider permanently discontinuing this drug.
- Recurrent Grade 4 AST or ALT increased: Permanently discontinue this drug.
- Grade 2: If no improvement within 2 weeks, withhold this drug until Grade 0 or 1; resume at same dose.
- Grade 3: Withhold this drug until Grade 0 or 1; resume at same dose if first occurrence or reduce dose if recurrent.
- Grade 4: Permanently discontinue this drug.
- Recurrent Grade 2 or first occurrence of any Grade 3: Withhold this drug for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug.
- First occurrence of any Grade 4: Permanently discontinue this drug OR withhold for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug.
- Recurrent Grade 3: Consider permanently discontinuing this drug.
- Recurrent Grade 4: Permanently discontinue this drug.
DOSE MODIFICATIONS FOR COADMINISTRATION OF STRONG OR MODERATE CYP450 3A4 INHIBITORS:
Avoid concurrent use of strong or moderate CYP450 3A4 inhibitors during therapy with this drug. If concomitant use of a strong or moderate CYP450 3A4 inhibitor is unavoidable, reduce the dose of this drug as follows:
Current daily dose 450 mg:
- Dose for coadministration with moderate CYP450 3A4 inhibitor: 225 mg
- Dose for coadministration with strong CYP450 3A4 inhibitor: 150 mg
- Dose for coadministration with moderate CYP450 3A4 inhibitor: 150 mg
- Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg
- Dose for coadministration with moderate CYP450 3A4 inhibitor: 75 mg
- Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg
- Dose for coadministration with moderate CYP450 3A4 inhibitor: 75 mg
- Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg (
Precautions
CONTRAINDICATIONS:
- None
This drug is not recommended for use in children.
Consult WARNINGS section for additional precautions.
Dialysis
No adjustment recommended.
Other Comments
Administration advice:
- This drug may be taken with or without food.
- If a dose is missed, do not take it within 12 hours of the next dose.
- Do not take an additional dose if vomiting occurs after administration but continue with the next scheduled dose.
Storage requirements:
- Store at 20C to 25C (68F to 77F); excursions permitted between 15C and 30C (59F and 86F).
General:
- Do not use if safety seal under cap is broken or missing.
- Dispense in original bottle.
- Do not remove desiccant. Protect from moisture.
- Keep container tightly closed.
Frequently asked questions
More about encorafenib
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.